Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1180 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Cephalon Q1 revenues surge

The company has reported a net income of $211.61m, or $2.64 per diluted share, compared to $100.33m, or $1.35 per diluted share, for the same period last year.

Nycomed, Almirall sign COPD drug commercialization pact

The once-daily tablet roflumilast is an orally administered phosphodiesterase 4 (PDE4) enzyme inhibitor. Data from four randomized placebo controlled trials have shown that roflumilast reduces exacerbations and improves

Sanofi-aventis, MMV sign malaria research pact

Under the agreement, both the parties will jointly work for identifying, characterizing and optimizing new treatments for malaria. The ‘Orthology Malaria’ project aims at developing drug candidates from

BioClinica Q1 revenues up

For the first quarter of 2011, the company has reported a net income of $351,000, or $0.02 per diluted share, compared to $711,000 or $0.05 per diluted share,